BiotechTubeBiotechTube
Home/Pipeline/IO112

IO112

Solid Tumors

Pre-clinicalActive

Key Facts

Indication
Solid Tumors
Phase
Pre-clinical
Status
Active
Company
IO Biotech

About IO Biotech

IO Biotech is developing a new class of therapeutic cancer vaccines based on its proprietary T-win® technology, which targets immune-suppressive molecules like IDO1 and PD-L1. The company's lead candidate, IO102-IO103 (Cylembio®), has shown promising clinical activity in combination with anti-PD-1 therapy in advanced melanoma. Following a strategic review and recent corporate restructuring, IO Biotech is exploring strategic alternatives to advance its pipeline.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

DrugCompanyPhase
GSK4362676GSK plcPhase 1
ABBV-154AbbViePhase 1
TAK-981Takeda PharmaceuticalPhase 1/2
TAK-676Takeda PharmaceuticalPhase 1
TAK-573Takeda PharmaceuticalPhase 1
TAK-164Takeda PharmaceuticalPhase 1
SHR-1316Jiangsu Hengrui MedicinePhase 1/2
BAY 2927088BayerPhase 1
ASP1929Astellas PharmaPhase 2
IBI188Innovent BiologicsPhase 1
Bispecific AntibodyAkesoPhase 1/2
CSPC-DM02CSPC Pharmaceutical Group LimitedPhase 2